SCHEMBL8624010

SCHEMBL8624010

C1CC2(CC2)CO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16877593 0.94 TTR (0.38)
SCHEMBL16878424 0.93 TTR (0.33)
SCHEMBL9147095 0.89
SCHEMBL5641872 0.87
SCHEMBL16877662 0.87
SCHEMBL565958 0.86 CYP11B1 (0.33)
SCHEMBL16878482 0.86
SCHEMBL16877394 0.86 TTR (0.33)
SCHEMBL873126 0.84 CYP11B1 (0.31)
SCHEMBL4437953 0.84 CYP11B1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138970-A1 MODULATORS OF THE CALCIUM SIGNALING CASCADE FONDAZIONE TELETHON ETS (IT) 2026-05-21 US claimed
EP-4608397-A1 MODULATORS OF THE CALCIUM SIGNALING CASCADE Fondazione Telethon ETS (IT) 2025-09-03 EP claimed
EP-4077334-B1 FUROINDAZOLE DERIVATIVES BAYER AG (DE) 2025-03-12 EP claimed
WO-2024089296-A1 MODULATORS OF THE CALCIUM SIGNALING CASCADE FONDAZIONE TELETHON ETS (IT) 2024-05-02 WO claimed
EP-0585678-B1 Process of preparing reduction products of 4-hydroxybutyric acid derivatives BASF AG (DE) 1998-06-17 EP claimed
US-20260138970-A1 MODULATORS OF THE CALCIUM SIGNALING CASCADE FONDAZIONE TELETHON ETS (IT) 2026-05-21 US disclosed
WO-2026099404-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER QUBIT PHARMACEUTICALS (FR) 2026-05-15 WO disclosed
EP-4741375-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER Qubit Pharmaceuticals (FR) 2026-05-13 EP disclosed
EP-4727939-A1 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS Prothena Biosciences Limited (IE) 2026-04-22 EP disclosed
EP-4729515-A1 NEW ACYLSULFONAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER Qubit Pharmaceuticals (FR) 2026-04-22 EP disclosed
US-12516039-B2 N-linked isoquinoline amides as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-01-06 US disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
US-20120309738-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-06 US disclosed
US-20120309755-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-06 US disclosed
US-20120309738-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-06 US disclosed
WO-2012076674-A1 IMIDAZO(4,5-B)PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 WO disclosed
US-20120149676-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 US disclosed
US-20120149676-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 US disclosed
WO-2012076672-A1 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 WO disclosed
WO-2012076673-A1 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-14 WO disclosed